Latest News about SNY
Recent news which mentions SNY
Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
February 01, 2024
From Benzinga
French Pharma Giant Sanofi's Q4 Earnings Hit By Aubagio Generic Competition, Helped By Flagship Eczema And Newly Launched Hemophilia Drugs
February 01, 2024
From Benzinga
Nasdaq Futures Rebound As Traders Eye Apple, Meta, Amazon Earnings: Analyst Flags 'January Barometer' That Bodes Well For The Year
February 01, 2024
From Benzinga
MaxLinear Reports Q4 Results, Joins ING, Wolfspeed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
February 01, 2024
From Benzinga
Earnings Scheduled For February 1, 2024
February 01, 2024
From Benzinga
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
January 29, 2024
From Benzinga
Regeneron/Sanofi's Largest Selling Drug Dupixent Scores FDA Approval For Infants With Esophagus Inflammation
January 26, 2024
From Benzinga
French Drugmaker Sanofi Agrees To Buy Inhibrx's Candidate For Rare Genetic Indication, For About $2.2B
January 23, 2024
From Benzinga
Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of Inhibrx Project
January 23, 2024
From Benzinga
Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades
January 22, 2024
From Benzinga
Sanofi's Olympic Endeavor: Leap Into Olympic Sponsorship Signals Cultural Transformation
January 10, 2024
From Benzinga
China Approves AstraZeneca-Sanofi's Respiratory Syncytial Virus Drug To Prevent Infection In Infants
January 02, 2024
From Benzinga
Expensive Drugs For Americans In 2024? Drugmakers Including Pfizer, Sanofi Mull Price Increase In January
December 29, 2023
From Benzinga
Why First Wave BioPharma Shares Are Skyrocketing Today
December 27, 2023
From Benzinga
From Benzinga
European Drugmaker Sanofi Ends Tusamitamab Ravtansine Lung Cancer Program After Disappointing Data
December 21, 2023
Tickers
SNY
From Benzinga
First Wave BioPharma To Acquire ImmunogenX To Bolster Gastrointestinal-Focused Pipeline
December 18, 2023
From Benzinga
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
December 17, 2023
From InvestorPlace
It's Almost 2024: 3 Top Stocks to Buy Before the New Year
December 17, 2023
From Motley Fool
French Drugmaker Sanofi Secures European Medicines Agency's Positive Opinion For Sleeping Sickness Treatment
December 15, 2023
Tickers
SNY
From Benzinga
3 Stocks to Buy Before 2024 That Can Set You Up For Life
December 14, 2023
From Motley Fool
French Pharma Giant Sanofi Drops Rare Disease Drug Pact As Federal Trade Commission Puts Antitrust Obstacle
December 12, 2023
Tickers
SNY
From Benzinga
Vanda Pharmaceuticals Acquires Rights To Multiple Sclerosis Drug From Johnson & Johnson's Company
December 07, 2023
From Benzinga
Sanofi Lays Out Ambitious Plans To Bolster Its Pipeline, Highlights 12 Blockbuster Opportunities
December 07, 2023
Tickers
SNY
From Benzinga
IGM Biosciences Increases Focus On Autoimmune Diseases, Stops All Blood Cancer-Related Studies
December 06, 2023
From Benzinga
Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis
December 06, 2023
From Benzinga
Investor Demand for Clarity Grows Amid Sanofi's Strategic R&D Shift
December 05, 2023
Tickers
SNY
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
More ways to get to us
Facebook
Twitter
YouTubeContact the Lethbridge Herald
504 - 7th Street South
Lethbridge, AB T1J 3Z7
[P] (403) 328-4411
[F] (403)328-4536
Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433
© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.